hexaminolevulinate
Formulary restricted to urology for the FDA approved indication. Outpatient use is planned.
Reviewed: Feb. 2022 (Cysview)
Formulary restricted to urology for the FDA approved indication. Outpatient use is planned.
Reviewed: Feb. 2022 (Cysview)